Outsourcing lead optimisation - The quiet revolution

Drug Discovery Today

Volumn 9, Issue 11, 2004, Pages 492-500

  Clark, David E ^a   Newton, Christopher G ^a  

^a Argenta Discovery Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ATTITUDE; COMMERCIAL PHENOMENA; COMPETITION; DRUG INDUSTRY; DRUG MARKETING; EUROPE; FORCE; HEALTH SERVICE; MOLECULAR BIOLOGY; REVIEW; UNITED STATES;

DRUG DESIGN; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; OUTSOURCED SERVICES; RESEARCH; RESEARCH DESIGN;

EID: 2442544477     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03102-2     Document Type: Review

References (32)

1. Cavalla D. The extended pharmaceutical enterprise. Drug Discov. Today. 8:2003;267-274
2. The Market for Lead Optimization Tools and Services. Applying the new '-omics' to enhance drug discovery. Kalorama Information, November 2003, p. 5
3. The Market for Lead Optimization Tools and Services. Applying the new '-omics' to enhance drug discovery. Kalorama Information, November 2003, p. 14
4. Baxter A.D., Lockey P.M. Hit-to-lead and lead-to-candidate optimisation using multi-parametric principles. Drug Discov. World. 2:2001;9-15
5. Drews J. Strategic trends in the drug industry. Drug Discov. Today. 8:2003;267-274
6. Rosenberg M., Mackenzie-Lawrie S. Innovation, efficiency and outsourcing. Scrip Magazine. May 2003;45-47
7. McCoy M., Tremblay J-F. Tapping foreign brains for profit. Chem. Eng. News. 81:2003;15-23
8. Tremblay J-F. Speeding up drug discovery: south Indian entrepreneurs offer contract research services to global pharma. Chem. Eng. News. 80:2002;13-17
9. Rouhi A.M. Betting on natural products for cures. Chem. Eng. News. 81:2003;93-103
10. Rouhi A.M. Custom synthesis for drug discovery. Chem. Eng. News. 81:2003;75-78
11. Short P.L. UK turns to drug discovery. Chem. Eng. News. 80:2002;14-16
12. Aldridge S. Argenta seeks to streamline drug discovery. Genet. Eng. News. 22:2002;13
13. 2 2, 32-34
14. Mullin R. Drug discovery: pure science yields to applied science as the genomics revolution focuses its energy on commercialization. Chem. Eng. News. 81:2003;21-31
15. Rouhi A.M. Moving beyond natural products. Chem. Eng. News. 81:2003;104-107
16. 2 2, 28-32
17. 2 2, 30-33
18. 2 2, 36-38
19. 2 2, 22-25
20. McCoy M. Starting over: chemists, other scientists turn closure of Pfizer labs in Kalamazoo into business opportunity. Chem. Eng. News. 81:2003;17-18
21. Rouhi A.M. Custom chemicals: fine chemicals companies grapple with the intricacies of supplying chemicals and services to the pharmaceutical industry. Chem. Eng. News. 82:2004;25-40
22. McCoy M. British firms are growing despite obstacles. Chem. Eng. News. 81:2003;18-19
23. Mullin R. Pharmacopeia set to split in two. Chem. Eng. News. 82:2004;1
24. Reisch M.S. Triangulating biotechnology: academic excellence, venture capital, and state support make North Carolina a growth nexus. Chem. Eng. News. 81:2003;16-21
25. 2 3, 33-35
26. McCoy M. Merck embraces offshore outsourcing. Chem. Eng. News. 81:2003;21
27. Koppal T. Finding new drugs through alliances. Drug Discov. & Development. December 2003;22-28
28. Verma P. Top pharma, biotech cos keen to outsource $200 M research. The Financial Express. 8 December 2003;. (http://www.financialexpress. com/fearchive_frame.php)
29. Anon. (2003) Lilly in novel China research tie-up. Scrip World Pharmaceutical News 2907, 11
30. Miller J. Outsourcing is front page news in 2003. Pharm. Technol. October 2003;168-169
31. Bruno J. US fine chemicals fighting a losing battle. Scrip Magazine. December 2003;20-21
32. Ghangurde A. India looks to 2005. Scrip Magazine. October 2003;31-32